How long does it take for women to start preparing for pregnancy after stopping taking obeticholic acid?

Obeticholic acid is an FXR agonist used to treat cholestatic liver diseases such as primary biliary cholangitis (PBC). It improves liver function and delays disease progression by regulating liver bile synthesis and excretion. Although this drug is widely used to treat hepatobiliary diseases in Europe, the United States and other countries, it has not yet been approved for marketing in China. For female patients of childbearing age, how to scientifically arrange their fertility plan during obeticholic acid treatment has become a key issue of clinical concern.

According to the drug labeling and relevant guidelines, obeticholic acid has not been adequately studied to determine its direct effects on human pregnancy. Although animal experiments have not shown strong teratogenicity, it is still recommended to be contraindicated during pregnancy, mainly because of the potential risk to fetal liver development. In addition, the regulatory effect of FXR receptor on bile metabolism during the embryonic period has not been fully understood, and it is theoretically possible to interfere with fetal bile salt homeostasis. Therefore, for women planning pregnancy, obeticholic acid discontinuation arrangements need to be scientifically evaluated based on pharmacokinetic characteristics and individual conditions.

The half-life of obeticholic acid is approximatelyabout 6 days, and it can continue to exist in the body for a certain period of time after enterohepatic circulation. Therefore, it is generally recommended to wait for at least 5 half-lives, that is, a clearance period of approximately more than 30 days, after stopping the drug to ensure that the drug concentration in the body is basically reduced to a negligible level. In addition, liver function monitoring should also be coordinated during this period to ensure the stability of liver enzyme indicators and to avoid fluctuations in underlying diseases due to drug withdrawal, thereby affecting the safety of pregnancy. For women with autoimmune diseases, it is even more necessary to develop an individualized pregnancy preparation strategy in collaboration with liver disease specialists and obstetricians and gynecologists.

It is worth emphasizing that if obeticholic acid is used as part of a combination therapy, such as with ursodeoxycholic acid (UDCA), the effects of other drugs should also be considered in the overall fertility plan. It is recommended to avoid the use of drugs that may potentially affect ovarian function during the withdrawal period, and to supplement appropriate amounts of folic acid and strengthen nutritional support.

Reference materials:https://en.wikipedia.org/wiki/Obeticholic_acid